Deutsch English Français

Contact

EP2152267

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2152267

EP2152267 - TREATMENT OF IMATINIB RESISTANT LEUKEMIA WITH BOSUTINIB [Right-click to bookmark this link]
Former [2010/07]	TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES
	[2014/38]
Status	The application is deemed to be withdrawn Status updated on 13.05.2016 Database last updated on 25.09.2024
Most recent event Tooltip	13.05.2016	Application deemed to be withdrawn	published on 15.06.2016 [2016/24]
Applicant(s)	For all designated states Wyeth LLC 235 East 42nd Street New York, NY 10017-5755 / US
	[2014/10]
Former [2010/16]	For all designated states Wyeth LLC Five Giralda Farms Madison, NJ 07940 / US
Former [2010/07]	For all designated states Wyeth LLC Five Giralda Farms Madison NJ 07940 / US
Inventor(s)	01 / HEWES, Becker 45 Myrtle Terrace Winchester, Massachusetts 01890 / US
	[2010/07]
Representative(s)	Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
	[2012/33]
Former [2010/32]	Lane, Graham Mark Hamilton, et al Pfizer Limited, European Patent Department Ramsgate Road Sandwich, Kent CT13 9NJ / GB
Former [2010/20]	Talbott, Dawn Jacqueline Wyeth Pharmaceuticals Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH / GB
Former [2010/07]	Talbott, Dawn Jacqueline Wyeth Laboratories Patent Department Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH / GB
Application number, filing date	08769857.7	30.05.2008
	[2010/07]
	WO2008US65215
Priority number, date	US20070932650P	01.06.2007 Original published format: US 932650 P
	[2010/07]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2008150957
	Date:	11.12.2008
	Language:	EN
	[2008/50]
	Type:	A2 Application without search report
	No.:	EP2152267
	Date:	17.02.2010
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.12.2008 takes the place of the publication of the European patent application.
	[2010/07]
Search report(s)	International search report - published on:	EP	06.08.2009
Classification	IPC:	A61K31/4709, A61K31/496, A61P35/02	[2015/07]
	CPC:	A61K31/4709 (EP,KR,US); A61K31/496 (EP,KR,US); A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP)
	C-Set:	A61K31/4709, A61K2300/00 (EP,US); A61K31/496, A61K2300/00 (US,EP)
	Former IPC [2014/38]	A61K31/496, A61P35/02
	Former IPC [2010/07]	A61K31/4709, A61K31/496, A61P35/02
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/07]
Title	German:	BEHANDLUNG VON IMATINIBRESISTENTER LEUKÄMIE MIT BOSUTINIB	[2014/38]
	English:	TREATMENT OF IMATINIB RESISTANT LEUKEMIA WITH BOSUTINIB	[2014/38]
	French:	TRAITEMENT DE LEUCÉMIE RÉSISTANT À L'IMATINIB AVEC BOSUTINIBE	[2014/38]
	Former [2010/07]	BEHANDLUNG VON IMATINIBRESISTENTER LEUKÄMIE UNTER VERWENDUNG VON AMINOCHINOLIN-3-CARBONITRILEN
	Former [2010/07]	TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES
	Former [2010/07]	TRAITEMENT DE LEUCÉMIE RÉSISTANT À L'IMATINIB EN UTILISANT DES 4-AMINOQUINOLEINE-3-CARBONITRILES
Entry into regional phase	30.11.2009	National basic fee paid
	30.11.2009	Designation fee(s) paid
	30.11.2009	Examination fee paid
Examination procedure	30.11.2009	Examination requested [2010/07]
	24.03.2010	Despatch of a communication from the examining division (Time limit: M06)
	01.10.2010	Reply to a communication from the examining division
	25.08.2014	Communication of intention to grant the patent
	15.10.2014	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	23.01.2015	Communication of intention to grant the patent
	02.06.2015	Fee for grant paid
	02.06.2015	Fee for publishing/printing paid
	21.07.2015	Despatch of a communication from the examining division (Time limit: M04)
	01.12.2015	Application deemed to be withdrawn, date of legal effect [2016/24]
	11.01.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/24]
Divisional application(s)	EP12160638.8 / EP2478905
	EP14167958.9 / EP2777704
	EP15191756.4 / EP3002009
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.03.2010
Fees paid	Renewal fee
	31.03.2010	Renewal fee patent year 03
	10.05.2011	Renewal fee patent year 04
	21.03.2012	Renewal fee patent year 05
	26.03.2013	Renewal fee patent year 06
	26.03.2014	Renewal fee patent year 07
	01.06.2015	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[A]US2005101780 (BOSCHELLI FRANK [US], et al);
		[Y]WO2006124863 (IRM LLC [US], et al) [Y] 13,21,25 * paragraph [0026] *;
		[DXY] - PUTTINI, MIRIAM ET AL, "In vitro and in vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib - Resistant Bcr - Abl + Neoplastic Cells", CANCER RESEARCH, (2006), vol. 66, no. 23, pages 11414 - 11322, XP002508641 [DX] 1-7,10,12,14-18,20,22-24 * abstract * * table 1 * [Y] 8,9,13,21,25 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-06-1199
		[X] - JABBOUR ELIAS ET AL, "New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance", SEMINARS IN HEMATOLOGY, PHILADELPHIA, PA, US, (20070101), vol. 44, no. 1 Suppl. 1, ISSN 0037-1963, pages s25 - s31, XP009086255 [X] 1-7,10,12,14-18,20,22-24 * page 28, column R, paragraph 2 - page 29, column L, paragraph 2 * DOI: http://dx.doi.org/10.1053/j.seminhematol.2006.12.003
		[Y] - BOSCHELLI, DIANE H. ET AL, "7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases", JOURNAL OF MEDICINAL CHEMISTRY, (2004), vol. 47, no. 7, pages 1599 - 1601, XP002508643 [Y] 8,9 * table 1 * * Scheme 3 * * page 1599, column 1 * DOI: http://dx.doi.org/10.1021/JM0499458
		[A] - GUMIREDDY KIRANMAI ET AL, "A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 8 FEB 2005, (20050208), vol. 102, no. 6, ISSN 0027-8424, pages 1992 - 1997, XP002508642 [A] 13,21,25 * the whole document * DOI: http://dx.doi.org/10.1073/PNAS.0408283102
		[A] - BOSCHELLI, DIANE H. ET AL, "Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2003), vol. 13, no. 21, pages 3797 - 3800, XP002508644 DOI: http://dx.doi.org/10.1016/J.BMCL.2003.07.001
		[A] - JABBOUR, ELIAS ET AL, "Current and emerging treatment options in chronic myeloid leukemia", CANCER (HOBOKEN, NJ, UNITED STATES), (20070412), vol. 109, no. 11, pages 2171 - 2181, XP002508645 [A] * page 2176, column L * DOI: http://dx.doi.org/10.1002/CNCR.22661
		[DA] - MERCEDES E. GORRE ET AL., "Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification", SCIENCE, (2001), vol. 293, pages 876 - 880, XP002508646 DOI: http://dx.doi.org/10.1126/science.1062538
		[DA] - LE COUTRE P ET AL, "Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.", BLOOD 1 MAR 2000, (20000301), vol. 95, no. 5, ISSN 0006-4971, pages 1758 - 1766, XP002508647
		[A] - GOLAS J M ET AL, "SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases,Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, (20030101), vol. 63, no. 2, pages 375 - 381, XP002283612
	Examination	- GUMIREDDY KIRANMAI ET AL, "A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (20050208), vol. 102, no. 6, doi:10.1073/PNAS.0408283102, ISSN 0027-8424, pages 1992 - 1997, XP002508642 DOI: http://dx.doi.org/10.1073/PNAS.0408283102
		- PUTTINI MIRIAM ET AL, "In vitro and in vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib - Resistant Bcr - Abl + Neoplastic Cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20060101), vol. 66, no. 23, doi:10.1158/0008-5472.CAN-06-1199, ISSN 0008-5472, pages 11414 - 11322, XP002508641 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-06-1199
	by applicant	- PUTTINI ET AL., "SKI-606, a novel Src-Abl inhibitor is effective at reducing replication of imatininb resistant CML cell lines having certain mutations associate with imatinib resistance.", CANCER RES., (20061201), vol. 66, no. 23

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p